Intact Investment Management Inc. Acquires 6,680 Shares of Becton, Dickinson and Company (NYSE:BDX)

Intact Investment Management Inc. raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 42.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 22,350 shares of the medical instruments supplier’s stock after buying an additional 6,680 shares during the period. Intact Investment Management Inc.’s holdings in Becton, Dickinson and Company were worth $5,389,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Old North State Wealth Management LLC lifted its stake in Becton, Dickinson and Company by 4.2% during the third quarter. Old North State Wealth Management LLC now owns 19,642 shares of the medical instruments supplier’s stock worth $4,744,000 after purchasing an additional 786 shares during the last quarter. Forum Financial Management LP lifted its position in Becton, Dickinson and Company by 39.0% in the 3rd quarter. Forum Financial Management LP now owns 2,467 shares of the medical instruments supplier’s stock worth $595,000 after buying an additional 692 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Becton, Dickinson and Company by 62.0% in the third quarter. Robeco Institutional Asset Management B.V. now owns 42,013 shares of the medical instruments supplier’s stock worth $10,129,000 after buying an additional 16,074 shares in the last quarter. Veritas Asset Management LLP grew its position in Becton, Dickinson and Company by 9.0% during the third quarter. Veritas Asset Management LLP now owns 2,295,205 shares of the medical instruments supplier’s stock valued at $553,374,000 after acquiring an additional 189,520 shares during the last quarter. Finally, Fort L.P. bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $226,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Price Performance

BDX opened at $234.33 on Tuesday. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $259.92. The company has a market cap of $67.73 billion, a price-to-earnings ratio of 48.22, a price-to-earnings-growth ratio of 1.75 and a beta of 0.43. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70. The stock has a fifty day simple moving average of $237.52 and a two-hundred day simple moving average of $235.10.

Analysts Set New Price Targets

BDX has been the topic of a number of analyst reports. Raymond James decreased their target price on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research report on Friday, August 2nd. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Stifel Nicolaus upped their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their target price for the company from $255.00 to $275.00 in a research note on Tuesday, October 1st. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $282.63.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.